Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 12, 2026

My wife and I are 79, barely surviving on $2K in Social Security. We’re terrified our money won’t last: What can we do?

View original at finance.yahoo.com
My wife and I are 79, barely surviving on $2K in Social Security. We’re terrified our money won’t last: What can we do? visootu2 / Envato Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Concerning developments could be coming for U.S. stocks, raising alarm bells for retirees

    80% confidence
  • Average annual spending for U.S. households ages 75 years and older was $55,834 in 2024

    80% confidence
  • With $50,000 in savings invested at 5% average annual return, you can afford nine yearly withdrawals of around $6,730 or $573 per month

    80% confidence
  • One asset will surge 400% in a year

    80% confidence
  • Average 79-year-old American female has 10.1 years of life remaining

    80% confidence
  • Retirees should aim to keep 18 to 24 months of essential expenses in their emergency fund

    80% confidence
  • Wealthfront's 3.95% APY is over ten times the national deposit savings rate as of January 2026

    80% confidence
  • Average 79-year-old American male has 8.6 years of life remaining

    80% confidence
  • Many people regret taking Social Security at age 62 and living to age 92 because it doesn't cover anything

    80% confidence
  • Average American over age 75 spent $7,168 on food in 2024

    80% confidence
  • Average American over age 75 spent $6,855 on transportation in 2024

    80% confidence
  • Average cost to insure a motor vehicle increased by over 60% between December 2020 and 2025

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com